rs7216389 — GSDMB ORMDL3 17q21 asthma risk

Intronic GSDMB variant that acts as an eQTL for ORMDL3; the T allele elevates ORMDL3 expression in airway cells, increasing sphingolipid-pathway ER stress and childhood asthma susceptibility

See your personal result for GSDMB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ORMDL3 17q21 — The Strongest GWAS Signal for Childhood Asthma

The chromosome 17q21 locus is the most replicated genetic risk factor for childhood-onset asthma ever identified. A dense block of linked variants spans six genes — IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA — and rs7216389, an intronic variant within GSDMB, serves as the most widely studied index SNP for this region11 serves as the most widely studied index SNP for this region
rs7216389 was identified as the top associated SNP in the Moffatt et al. 2007 landmark GWAS and has been used as the index SNP for the 17q21 asthma locus in hundreds of subsequent studies. The T allele increases ORMDL3 expression in airway epithelial cells and immune cells, activating an inflammatory cascade specific to early life.

The Mechanism

rs7216389 is an intronic expression quantitative trait locus (eQTL)22 intronic expression quantitative trait locus (eQTL)
An eQTL is a genetic variant that alters the transcript level of a nearby gene without changing the protein sequence; rs7216389 acts in cis to regulate both ORMDL3 and GSDMB expression in a genotype-dependent manner in the GSDMB gene. Individuals carrying the T allele produce significantly higher levels of ORMDL3 mRNA and protein in airway epithelial cells, bronchial tissue, and lymphoblastoid cell lines compared with C-allele homozygotes. The TT genotype shows the highest expression; CC shows the lowest, with CT intermediate in a dose-dependent additive pattern.

ORMDL3 encodes an ER-resident transmembrane protein that inhibits serine palmitoyltransferase33 ORMDL3 encodes an ER-resident transmembrane protein that inhibits serine palmitoyltransferase
Serine palmitoyltransferase (SPT) is the rate-limiting enzyme for de novo sphingolipid biosynthesis; ORMDL3 acts as a negative regulator of SPT activity, the rate-limiting enzyme in sphingolipid synthesis. Paradoxically, elevated ORMDL3 expression decreases sphingolipid levels in the cell — TT epithelial cells show measurably reduced dihydroceramide and ceramide concentrations compared with CC cells. This sphingolipid deficit disrupts the physical properties of the plasma membrane, alters T-cell receptor signaling thresholds, and promotes a Th2-skewed immune environment.

Simultaneously, ORMDL3 overexpression perturbs ER calcium homeostasis, activates the unfolded protein response via ATF6, and induces NF-κB signaling — converging on increased production of the chemokines IL-8 and CCL-20, the protease ADAM-8, and adhesion molecule ICAM-1 in airway epithelial cells, all of which amplify eosinophilic airway inflammation.

The Evidence

The landmark Moffatt et al. 2007 GWAS in Nature44 landmark Moffatt et al. 2007 GWAS in Nature
994 childhood asthma cases vs 1,243 controls in a British family-based and case-referent panel; rs7216389 was associated at p<10⁻¹² was the first genome-wide significant finding for asthma. A single T allele conferred OR 1.50 (95% CI 1.24–1.81); two T alleles conferred OR 2.11 (95% CI 1.71–2.61). ORMDL3 expression in lymphoblastoid cells correlated more strongly with rs7216389 than with any other SNP at the locus.

A 2017 childhood asthma meta-analysis55 2017 childhood asthma meta-analysis
Su et al. 2017, pooling 10+ studies in children, T vs C allele OR 1.89 (95% CI 1.57–2.27) in pediatric populations; no association with adult-onset asthma (OR 1.02, p=0.81) confirmed the association is specific to childhood onset. The 2015 Shi et al. meta-analysis66 2015 Shi et al. meta-analysis
13 studies, 6,462 cases and 7,357 controls; ORMDL3 polymorphisms including rs7216389 significantly associated with asthma susceptibility replicated consistently across ethnicities.

The most striking evidence comes from gene-environment interaction studies. Caliskan et al. 2013 in the NEJM77 Caliskan et al. 2013 in the NEJM
Two independent birth cohorts (COAST, COPSAC) with prospective viral-illness tracking; HRV wheezing × TT genotype interaction p=0.004 found that the 17q21 TT genotype dramatically increased asthma risk only in children who had experienced rhinovirus (HRV)-associated wheezing in early life: OR 26.1 (95% CI 5.1–133) for TT + early HRV wheezing vs. no risk alleles and no HRV illness. Children with TT but no early HRV wheezing showed no excess asthma risk. RSV wheezing did not produce the same interaction.

Pharmacogenomically, Verlaan et al. 200888 Verlaan et al. 2008
Asthmatic children and young adults followed prospectively; T allele carriers showed more exacerbations and worse spirometry despite treatment demonstrated that T allele carriers have asthma that responds less well to standard inhaled corticosteroids, with more exacerbations and poorer medication control compared to CC individuals. A 2024 pharmacogenomics study99 2024 pharmacogenomics study
ICS response analysis in two pediatric cohorts (PrecisionLink Biobank + BIG Initiative); GSDMB/ORMDL3 rs7216389 significantly associated with ICS response in White children; TT homozygotes showed increased exacerbation risk despite ICS replicated these findings in independent cohorts.

Practical Implications

For TT carriers, the primary clinical implication is heightened vigilance for childhood asthma, especially when combined with early-life viral wheezing illness (rhinovirus specifically). When asthma is present, T allele carriers — particularly TT homozygotes — are more likely to have exacerbation-prone disease that requires step-up therapy beyond standard ICS. Monitoring exhaled nitric oxide (FeNO) and blood eosinophil counts provides objective markers of eosinophilic airway inflammation, which is the mechanism-appropriate endotype for this locus.

The sphingolipid pathway connection is scientifically important but not yet clinically actionable via supplements or diet. The established actions center on monitoring, trigger avoidance specific to rhinovirus exposure, and structured pharmacotherapy review.

Interactions

rs7216389 is in strong LD with multiple other functional variants at 17q21, including rs2872507 (IKZF3), rs8076131, rs12936231 (GSDMB), and rs11650680. The locus has dual effects on immune regulation: the asthma risk (T) alleles are associated with lower autoimmune disease risk, while the autoimmune risk alleles at rs2872507 (A) are protective for asthma — reflecting the inverse relationship between Th2-driven atopy and Th17/B-cell-driven autoimmunity. Asthma compound risk from the rs7216389 T allele is amplified by co-occurring Th2 pathway variants (IL13 rs20541, IL4RA rs1801275) and by early-life rhinovirus wheezing, making this SNP particularly relevant in the context of atopic disease clustering.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

No elevated asthma risk from the ORMDL3 locus

You carry two copies of the C allele at rs7216389, the genotype associated with the lowest ORMDL3 expression at this locus. About 29% of the global population shares this genotype. The 17q21 locus does not contribute to elevated childhood asthma risk for you, and standard atopic disease monitoring is appropriate based on other factors.

CT Intermediate

One asthma-risk allele — moderately elevated ORMDL3 expression

The additive dose-response at rs7216389 means CT individuals sit between the two homozygous extremes. ORMDL3 expression in airway cells is intermediate, as are associated eosinophilic and Th2-skewed responses. For people with established asthma, CT individuals show somewhat poorer ICS response than CC, though the pharmacogenomic effect is more pronounced in TT homozygotes. Monitoring eosinophil count and FeNO helps identify whether eosinophilic airway inflammation is contributing to suboptimal asthma control.

TT High Risk

Two asthma-risk alleles — highest ORMDL3 expression, strongly elevated childhood asthma susceptibility

The TT genotype drives the highest level of ORMDL3 expression in airway epithelial cells, lymphoblastoid cells, and CD4+ T cells. Elevated ORMDL3 paradoxically suppresses serine palmitoyltransferase, reducing de novo ceramide and dihydroceramide synthesis — a sphingolipid deficit that lowers T-cell activation thresholds and promotes Th2 polarization. Simultaneously, ORMDL3 overexpression activates ATF6-mediated ER stress, induces NF-κB, and amplifies eosinophilic chemokine production (CCL-20, IL-8), ICAM-1 expression, and ADAM-8 protease activity in the airway epithelium.

The gene–environment interaction with rhinovirus is the most clinically important aspect of this genotype. The NEJM 2013 study by Caliskan et al. showed that TT individuals who experienced rhinovirus wheezing illnesses in the first 3 years of life had a 26-fold increased odds of developing asthma — a uniquely large effect size for a common genetic variant. The implication is that preventing severe early-life rhinovirus wheezing (through breastfeeding, childcare timing, and rapid treatment of wheezing episodes) may substantially reduce the actualized risk from this genotype.

Pharmacogenomically, TT homozygotes are most likely to have ICS-refractory exacerbation-prone asthma — the GSDMB/ORMDL3 locus associates with increased oral corticosteroid use and hospitalizations despite ICS in multiple cohorts. Biological step-up therapy targeting eosinophilic inflammation (anti-IL-5, anti-IL-4Rα) may be more appropriate for TT individuals with severe or uncontrolled asthma than escalating ICS alone.